Proteomic analysis for finding serum pathogenic factors and potential biomarkers in multiple myeloma.
- Author:
Hong-Tao ZHANG
;
En-Bing TIAN
;
Yu-Ling CHEN
;
Hai-Teng DENG
;
Qing-Tao WANG
1
Author Information
- Publication Type:Journal Article
- MeSH: Biomarkers; blood; Biomarkers, Tumor; blood; Humans; Multiple Myeloma; blood; Peptide Library; Proteomics; methods; Tandem Mass Spectrometry
- From: Chinese Medical Journal 2015;128(8):1108-1113
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDMultiple myeloma (MM) is a malignant tumor, which takes the second place in malignant blood disease. The clinical symptoms are complicated that make more difficult to diagnose and therapy. Lots of researches focus on the proteins about MM in order to solve those problems. We used proteomic methods to find potential biomarkers in MM patients.
METHODSWe applied the peptide ligand library beads (PLLBs) to deplete high abundance proteins in serum for finding potential pathogenic factors and biomarkers of MM. Using 1D-Gel-liquid chromatography-tandem mass spectrometry (LC-MS/MS), we identified 789 and 849 unique serum proteins in MM patients and in healthy controls, respectively.
RESULTSTwenty-two proteins were found differentially expressed between the two groups including serum amyloid A protein, vitamin D-binding protein isoform-1 precursor, plasma kallikrein, and apolipoprotein A-I. Changes of integrin alpha-11 and isoform-1 of multimerin-1 were validated with Western blotting. The linkage of the differentially expressed proteins and the pathogenesis pathways of MM were discussed.
CONCLUSIONSPLLB combined with 1D-gel-LC-MS/MS analysis is an efficient method to identify differentially expressed proteins in serum from patients with MM.